Overweight, Obese More Likely to Adhere to Statin Therapy
Heavy drinkers with cardiovascular comorbidities less likely to adhere to statin therapy
TUESDAY, June 24, 2014 (HealthDay News) -- Among patients with cardiovascular comorbidities, lifestyle factors predict nonadherence to statin therapy, according to research published online June 23 in the Canadian Medical Association Journal.
Heli Halava, M.D., of the University of Turku in Finland, and colleagues assessed the association between lifestyle factors and nonadherence to statin therapy in 9,285 participants (6,458 with cardiovascular comorbidities; 2,827 without cardiovascular comorbidities).
The researchers found sizable rates of nonadherence to statin therapy in participants without cardiovascular comorbidities (49.1 percent) and participants with cardiovascular comorbidities (40.9 percent). Among participants without cardiovascular comorbidities, predictors of decreased risk of nonadherence to statins included obesity (odds ratio [OR], 0.86; 95 percent confidence interval [CI], 0.74 to 0.99), overweight (OR, 0.88; 95 percent CI, 0.79 to 0.98), and former smoking (OR, 0.82; 95 percent CI, 0.74 to 0.92). Among participants with cardiovascular comorbidities, predictors of increased risk of nonadherence to statins included high levels of alcohol consumption (OR, 1.55; 95 percent CI, 1.12 to 2.15), extreme drinking events (OR, 1.48; 95 percent CI, 1.11 to 1.97), and a cluster of three to four lifestyle risks (OR, 1.61; 95 percent CI, 1.15 to 2.27).
"The association between lifestyle factors and nonadherence to statin therapy varied according to cardiovascular comorbidity status," the authors write.
One of the authors discloses financial ties to pharmaceutical companies.